Welcome to our dedicated page for Entero Therapeutics news (Ticker: ENTO), a resource for investors and traders seeking the latest updates and insights on Entero Therapeutics stock.
Entero Therapeutics Inc. (ENTO) is a clinical-stage biopharmaceutical leader developing non-systemic therapies for gastrointestinal disorders. This page provides investors and medical professionals with essential updates on ENTO's innovative pipeline, including oral biotherapeutics and enzyme replacement treatments targeting conditions like celiac disease and gastroparesis.
Discover timely press releases detailing clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection ensures efficient tracking of ENTO's advancements in localized GI therapies while maintaining compliance with financial disclosure standards.
Key updates include developments in latiglutenase for celiac management, capeserod for motility disorders, and adrulipase for pancreatic insufficiency. Bookmark this page to monitor ENTO's research breakthroughs and evidence-based therapeutic innovations without promotional bias.
Entero Therapeutics (NASDAQ:ENTO) launched Grid AI Corp. on October 16, 2025 to coordinate AI data center compute with electric grids. The company says rising AI demand will push global data center electricity beyond 1,000 TWh and that AI workloads account for over 30% of that growth, requiring more than $1 trillion in new energy and digital infrastructure investment.
Grid AI's platform claims to orchestrate and dispatch flexible data center loads in real time, unlocking stranded capacity, shortening interconnection timelines, and enabling participation in demand-response and ancillary markets. Analysts cited estimate flexible capacity (5–10%) could free >100 GW, accelerate deployments by up to 24 months, and create a $150–$200 billion annual addressable market for software and controls.
Entero Therapeutics (NASDAQ:ENTO) announced a strategic pivot by acquiring GRID AI, moving from biotech toward grid orchestration technology focused on behind-the-meter assets.
The deal highlights a $2.5 billion target market cited to quadruple by 2033, a platform built with more than $50 million of engineering investment, and a Dynamic Load Shaping and Aggregation Management Platform for EV chargers, rooftop solar, HVAC and batteries.
Post-transaction, GRID AI stakeholders hold more than 80% of Entero equity and the company has 1.69 million fully diluted shares, positioning the microcap to play in AI-driven energy orchestration.
Entero Therapeutics (NASDAQ:ENTO) announced a strategic transformation by acquiring GRID AI on October 14, 2025, repositioning the company from biotech to grid-edge energy orchestration.
Key facts: GRID AI has absorbed over $50 million of investment since 2019; the grid-edge sector cited is ~$2.5 billion; GRID AI shareholders will own >80% of Entero on a fully diluted basis, and Entero reports 1.69 million fully diluted shares.
The release frames the deal as a move to provide Dynamic Load Shaping and Aggregation Management for distributed assets (solar, EV chargers, HVAC) to address AI-driven energy demand; risks named include utility caution, regulatory friction, and multi-jurisdiction scaling challenges.
Entero Therapeutics (NASDAQ:ENTO) has announced a transformative acquisition of GRID AI Corp, positioning itself in the rapidly growing AI energy-infrastructure market. GRID AI's platform utilizes AI and machine learning to manage distributed energy resources and balance power supply and demand in real-time.
The deal structure gives GRID AI shareholders 82.5% ownership of ENTO's fully diluted common stock, while existing ENTO shareholders retain 17.5%. GRID AI's technology addresses the surging power demands from AI data centers, with Goldman Sachs projecting global data-center power demand to increase ~50% by 2027 and up to 165% by 2030 versus 2023 levels.
The acquisition leverages over $50 million invested in GRID AI since 2019, targeting a market expected to see AI infrastructure investments exceeding $2.8 trillion by 2029.
Entero Therapeutics (NASDAQ: ENTO) has announced the acquisition of GRID AI Corp, a grid-edge AI platform company, marking a strategic pivot into the AI energy infrastructure market. GRID AI's platform, which has received over $50 million in investment since 2019, specializes in Dynamic Load Shaping and Aggregation Management for behind-the-meter energy assets.
The transaction structure will result in GRID AI shareholders owning 82.5% of ENTO's fully diluted common stock, while existing ENTO shareholders will retain 17.5%. The deal includes board restructuring, with GRID AI shareholders initially appointing two directors and eventually controlling five of seven board seats.
This strategic acquisition positions ENTO in a high-growth market, as Goldman Sachs projects global data-center power demand to increase by ~50% by 2027 and up to 165% by 2030 versus 2023 levels, driven by AI infrastructure expansion.
Entero Therapeutics (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on GI disease therapies, announced a 1-for-3 reverse stock split effective August 18, 2025. The split will reduce outstanding shares from 4.77 million to approximately 1.59 million.
The reverse split aims to regain compliance with Nasdaq's minimum bid price requirement of $1.00 per share. Stockholders will receive cash in lieu of fractional shares. The company's interim CEO emphasized that maintaining Nasdaq listing visibility is crucial for enhancing shareholder value.
Entero Therapeutics (NASDAQ: ENTO), a clinical-stage biopharmaceutical company focused on GI diseases, has secured a $3 million private placement through the sale of pre-funded and common warrants. The offering includes 4,878,841 pre-funded warrants and 9,757,682 common warrants, with a combined purchase price of $0.6149 for one pre-funded warrant and two common warrants.
The pre-funded warrants have an exercise price of $0.00001 and are immediately exercisable. The common warrants, exercisable at $0.3649 per share, have a 5-year term. The company will receive $1 million at closing and the remaining $2 million upon registration statement effectiveness. The transaction is expected to close around August 11, 2025.
Entero Therapeutics (NASDAQ: ENTO) has announced signing a rescission agreement to unwind its business combination with ImmunogenX, (IMGX). The combination, originally announced on December 18, 2023, and closed on March 14, 2024, will be reversed pending shareholder approval required by June 30, 2025.
The company's CEO, Richard Paolone, stated that the decision to unwind the transaction was made following an internal review, aimed at strengthening the balance sheet and refocusing value creation strategy. The rescission will allow both companies to pursue independent strategic initiatives while maintaining a positive working relationship.
Additionally, Entero announced the appointment of Anna Skowron as Chief Financial Officer, effective March 3, 2025. Skowron brings 14 years of accounting experience, including expertise in financial reporting, compliance, and business strategy. She previously founded Skowron Accounting Professional and held positions as Global Financial Controller at a multinational technology provider.
Entero Therapeutics (Nasdaq: ENTO) has announced the appointment of Richard Paolone as interim CEO. Paolone, a Toronto-based securities lawyer, brings extensive experience in corporate finance, securities law, and mergers and acquisitions to the clinical-stage biopharmaceutical company.
Paolone's background includes advising on strategic business initiatives, representing companies in debt and equity securities offerings, and demonstrating comprehensive knowledge of capital markets and regulatory environments. He has been instrumental in numerous M&A and go-public transactions, and has served as a director or officer for multiple private and publicly traded companies.
Entero Therapeutics (NASDAQ: ENTO) has secured a $2 million revolving loan agreement and appointed three new Board members. The loan agreement required the replacement of three out of five Board members with directors designated by the lender. James Sapirstein, Alastair Riddell, and Timothy Ramdeen have resigned from the Board.
The new appointees are: Richard Paolone, a Toronto-based securities lawyer; Eric Corbett, a managing director with capital markets experience; and Manpreet Uppal, a professional with capital markets and real estate expertise. The financing aims to strengthen the company's balance sheet and provide working capital while bridging to an anticipated subsequent public offering.
FAQ
What is the current stock price of Entero Therapeutics (ENTO)?
What is the market cap of Entero Therapeutics (ENTO)?
